Drug intelligence / Profile preview

Prexa-NT

Development stage
Unknown
Lead developer
Prexa
Modality
Small Molecules
Administration
Oral
01

Overview

Prexa-NT is an oral fixed-dose combination medication developed by Atro Pharma for the management of neuropathic pain. It contains two active small molecule ingredients: pregabalin (75mg) and nortriptyline (10mg). Pregabalin acts as an alpha-2 delta ligand, binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system to reduce the release of excitatory neurotransmitters. Nortriptyline is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin, thereby enhancing descending inhibitory pain pathways. This synergistic combination is designed to alleviate chronic nerve pain, improve sleep quality, and support overall nerve health. It is typically administered once daily, preferably at bedtime.

Brand names
Prexa-NT
Other names
Prexa NT
02

Targets

SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)

Beyond the preview

Go deeper on Prexa-NT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prexa-NT.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call